10-K: CEL-SCI Reports Strong Multikine Phase III Data, Faces Going Concern Doubt

CEL-SCI Corporation's latest 10-K filing highlights positive Phase III Multikine data for head and neck cancer, outlining plans for a confirmatory study while facing ongoing financial losses and a going concern doubt.

Summary

• Multikine's Phase III study demonstrated a 73% 5-year survival rate in the target population (newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression) compared to 45% in the control group, with a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).
• No demonstrable safety signals or toxicities were observed in approximately 740 Multikine-treated subjects across multiple clinical trials.
• The FDA indicated CEL-SCI may move forward with a 212-patient randomized controlled confirmatory registration study for Multikine in the target population, which accounts for approximately 100,000 patients worldwide per year.
• The confirmatory study is estimated to cost approximately $30 million, and the company's ability to raise this capital is crucial for its initiation.
• Comprehensive Phase 3 trial results, including new quality of life data, were published in the peer-reviewed journal Pathology and Oncology Research (POR) in March 2025, showing a 46.5 months median OS advantage over standard of care in the low-risk group.
• The company reported a net operating loss of approximately $25.41 million for the fiscal year ended September 30, 2025, compared to $26.92 million in 2024.
• Cash and cash equivalents stood at approximately $11.0 million as of September 30, 2025.
• CEL-SCI raised net proceeds of approximately $25.0 million in fiscal year 2025 and $21.2 million in fiscal year 2024 through common stock sales and warrant exercises.
• A 1-for-30 reverse stock split of outstanding common stock became effective on May 20, 2025.
• Management identified material weaknesses in internal control over financial reporting as of September 30, 2025, related to logical access to IT systems and operating effectiveness of management review controls.

Sentiment

Score: 4

Explanation: While clinical data for Multikine is promising and addresses an unmet medical need, the company's severe financial distress, recurring losses, explicit 'going concern' doubt, and significant capital requirements for future development create substantial uncertainty and risk. The positive clinical results are overshadowed by the precarious financial position.

Positives

• Multikine's Phase III data shows a significant survival benefit in the target population, with a 73% 5-year survival rate compared to 45% in the control group.
• The hazard ratio of 0.35 (95% CIs [0.19, 0.66]) indicates a 65% reduction in the risk of death for Multikine-treated patients in the target population.
• No demonstrable safety signals or toxicities were observed in approximately 740 Multikine-treated subjects across multiple clinical trials, suggesting a favorable safety profile.
• Multikine addresses a significant unmet medical need for head and neck cancer patients with low PD-L1 expression, a population not well served by existing immunotherapies like Keytruda or Opdivo.
• The FDA has indicated that CEL-SCI may move forward with a confirmatory registration study for Multikine, providing a clear regulatory pathway.
• The company published comprehensive Phase 3 results, including positive quality of life data, in a peer-reviewed journal (Pathology and Oncology Research) in March 2025.
• The manufacturing facility commissioning was completed in February 2024, a crucial milestone for a future Biologics License Application (BLA).
• A Memorandum of Understanding (MOU) was signed with Dallah Pharma for Multikine commercialization in Saudi Arabia, and a Breakthrough Medicine Designation application has been filed with the SFDA.
• Existing licensing agreements are in place for Multikine in several international territories, including Israel, Turkey, Serbia, Croatia, Taiwan, Singapore, Malaysia, Hong Kong, Philippines, South Korea, Australia, New Zealand, and South Africa.

Negatives

• The company has incurred significant net losses since its inception, totaling approximately $539 million through September 30, 2025.
• CEL-SCI anticipates continued significant losses and negative operating cash flow for the foreseeable future and may never achieve or maintain profitability.
• There is substantial doubt about the company's ability to continue as a going concern without securing additional capital.
• Substantial additional capital, estimated at $30 million for the confirmatory study, is required to remain in operation, and there is no assurance it will be available on acceptable terms.
• The company is heavily dependent on the success of Multikine, with its other product candidates (LEAPS technology) still in preclinical development.
• Material weaknesses in internal control over financial reporting were identified as of September 30, 2025, indicating deficiencies in financial processes and controls.
• The price of CEL-SCI's common stock has been and is likely to continue to be volatile, potentially resulting in substantial losses for shareholders.
• A 1-for-30 reverse stock split was effected on May 20, 2025, which can sometimes be perceived negatively by the market.
• Net operating loss (NOL) and tax credit carryforwards of $6.7 million and $0.9 million, respectively, were eliminated or restricted due to identified changes in ownership, reducing future tax benefits.

Risks

• Incurred significant losses since inception and anticipates continued significant losses for the foreseeable future and may never achieve or maintain profitability.
• Will require substantial additional capital to remain in operation; a failure to obtain this necessary capital when needed could force delays, reductions, or termination of product candidates' development or commercialization efforts.
• The costs of product candidates' development and clinical trials are difficult to estimate and will be very high for many years, preventing profit for the foreseeable future, if ever.
• Has not established a definite plan for the marketing of Multikine, if approved.
• Depends heavily on the success of Multikine, for which Phase III data has been presented, while its other candidates are still in preclinical phases.
• Product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject to unanticipated delays or prevent marketing any products.
• Even if regulatory approval is obtained for investigational products, the company will be subject to stringent, ongoing government regulation.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.
• Biologics carry unique risks and uncertainties, which could have a negative impact on future operations.
• Current and future relationships with healthcare professionals, principal investigators, consultants, potential customers, and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.
• Commercial success depends, in part, upon attaining significant market acceptance of product candidates, if approved, among physicians, patients, healthcare payors, and major operators of cancer clinics.
• Patents might not protect technology from competitors, in which case the company may not have any advantage over competitors in selling any products that it may develop.
• Much of intellectual property is protected as trade secrets or confidential know-how, not by patents, which carries risks of disclosure or independent development by competitors.
• May experience future dilution as a result of future equity offerings or other equity issuances.
• The price of common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for shareholders.
• Identified material weaknesses in internal control over financial reporting; failure to achieve and maintain effective internal controls could adversely affect the ability to report results accurately and timely.
• Cybersecurity breaches could affect operations, compromise confidential information, or adversely affect operating results or business reputation.
• An adverse determination in any future legal proceedings could have a material adverse effect on the company.
• Compliance with changing regulations concerning corporate governance and public disclosure may result in additional expenses.
• May encounter problems, delays, and additional expenses in developing marketing plans with third parties.
• Difficulties hiring or retaining key personnel or managing growth could disrupt operations.
• If product liability or patient injury lawsuits are brought against the company, it may incur substantial liabilities and be required to limit clinical testing or future commercialization.
• Statements in this report about the efficacy and pathway of approval for Multikine are based on the company's analysis of its Phase III trial and are speculative in nature and may ultimately prove to be inaccurate or incorrect.
• Will need to conduct a Bridging study for the assay used in the confirmatory study to detect/determine the PD-L1 status of patients; disruption could delay timely submission of marketing approval to the FDA.
• May face substantial competition, which may result in others discovering, developing, or commercializing competing products more quickly or more successfully.
• May be unable to successfully scale-up manufacturing of its lead product candidate Multikine in sufficient quality and quantity, which would delay or prevent commercialization.
• Failure to obtain or maintain adequate coverage and reimbursement for the product candidates, if approved, could limit the ability to market those products and decrease the ability to generate revenue.
• Currently has no marketing and sales force; inability to establish effective sales or marketing capabilities or enter into agreements with third parties could hinder commercialization.
• Business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries.
• Healthcare legislative reform measures may have a material adverse effect on business and results of operations.
• Foreign governments often impose strict price controls, which may adversely affect future profitability.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties or incur costs that could harm the business.
• May be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• Section 382 of the Internal Revenue Code may limit the use of Net Operating Losses due to ownership changes.
• The exercise of outstanding warrants and options will cause dilution to holders of common stock.
• Since the company does not intend to pay dividends on its common stock, any potential return to investors will result only from any increases in the price of its common stock.

Future Outlook

The company plans to initiate a 212-patient confirmatory registration study for Multikine in the target population, with full enrollment anticipated in approximately 15 months, and aims to seek early approval following full enrollment. It also intends to pursue marketing authorization for Multikine in Canada, the United Kingdom, and Europe. The LEAPS technology remains in preliminary development, with the primary strategic focus on advancing Multikine towards commercialization.

Management Comments

• CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine (Leukocyte Interleukin, Injection).
• CEL-SCI believes Multikine significantly extended life.
• CEL-SCI believes Multikine leads to longer survival with no safety issues.
• CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine.
• CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.
• CEL-SCIs goal is to begin the 212-patient confirmatory registration study as soon as the needed capital has been raised, with full enrollment about 15 months later with the potential to seek early approval after full enrollment.
• CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study.
• CEL-SCI believes this represents a large unmet medical need in the rheumatoid arthritis market.
• CEL-SCI considers this [method of manufacture for Multikine as a trade secret] to be its best protection from competitors.
• CEL-SCIs management has engaged in fundraising for over 30 years and believes that the manner in which it is proceeding will produce the best possible outcome for the shareholders.

Industry Context

The global cancer immunotherapy market is a high-growth sector, projected to reach USD $196.45 billion by 2030 with a CAGR of 7.2%. Multikine is positioned uniquely within this market as a first-line immunotherapy administered before any other treatment, targeting newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression. This differentiates it from established checkpoint inhibitors like Keytruda and Opdivo, which are typically used after surgery or for patients with high PD-L1 expression, suggesting Multikine could serve a distinct and currently underserved patient population.

Comparison to Industry Standards

• Multikine's Phase III study demonstrated a 73% 5-year overall survival rate in its target population (low PD-L1, no lymph node involvement) compared to 45% in the control group, with a hazard ratio of 0.35, indicating a substantial survival benefit.
• Keytruda (Merck), a prominent checkpoint inhibitor, received FDA approval in June 2025 as a perioperative treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-L1 at a positive level.
• Merck's Phase III KEYNOTE-689 trial for Keytruda showed a 30% reduction in the risk of recurrence and progression but no improvement in overall survival, and importantly, patients with low to zero PD-L1 levels did not benefit.
• This contrast highlights Multikine's potential to address a different patient subset (low PD-L1) than Keytruda (high PD-L1), suggesting a complementary rather than directly competitive market position.
• The upper limit of Multikine's 95% confidence interval for the hazard ratio (0.66) is still below the threshold typically required for most drug approvals, reinforcing the statistical significance of its survival benefit.

Management Changes

Corporate Governance

Related Party Transactions

• Officers and a director purchased 32,116 shares of restricted common stock directly from the company at an aggregate market value of approximately $220,000 during the fiscal year ended September 30, 2025.
• Officers and a director purchased 1,933 shares of restricted common stock at an aggregate market value of approximately $81,000 during the fiscal year ended September 30, 2024.
• Geert Kersten, the CEO and a director, loaned the company $200,000 on July 11, 2024, and an additional $250,000 on July 18, 2024. These loans were repaid on July 30, 2024.
• On May 4, 2024, the company modified the terms of Series UU, X, Y, N, MM, NN, and RR warrants by extending their expiration dates by twenty-four months. These warrants are held by current officers (Geert Kersten, Patricia Prichep) and the de Clara Trust (of which Mr. Kersten is a beneficiary). The incremental cost of this extension was approximately $0.7 million, recorded as a deemed dividend.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity offerings, continued stock price volatility, and no planned common stock dividends. The fee-shifting bylaws may also discourage shareholder litigation.
• Employees, including executive officers, receive compensation through base salary, long-term incentives (stock options/grants), and benefits, including a 401(k) plan with company match. Some officers have deferred parts of their salaries to support the company.
• Patients with head and neck cancer, particularly those with low PD-L1 tumors, could significantly benefit from Multikine as a new, effective first-line immunotherapy with a strong safety profile, addressing a critical unmet medical need.
• Patients with rheumatoid arthritis may see future treatment options from the LEAPS technology, though these candidates are still in early preclinical development.
• Creditors face increased risk due to the company's recurring losses and the explicit 'going concern' doubt, which may impact the company's ability to meet its financial obligations.
• Regulatory bodies (FDA, Health Canada, EMA, MHRA, SFDA) are actively engaged in the review and approval processes for Multikine, indicating ongoing scrutiny and collaboration.

Next Steps

• Initiate the 212-patient confirmatory registration study for Multikine in the target population, contingent on securing the required capital.
• Achieve full enrollment for the confirmatory study within approximately 15 months.
• Seek early approval for Multikine after full enrollment of the confirmatory study.
• Pursue filings for marketing authorization for Multikine in Canada, the United Kingdom, and Europe.
• Develop a commercialization and regulatory partnership agreement with Dallah Pharma for Multikine in Saudi Arabia.
• Conduct a Bridging study for the PD-L1 assay in collaboration with a diagnostics testing partner to support marketing approval.
• Remediate identified material weaknesses in internal control over financial reporting.
• Continue preclinical development for LEAPS product candidates (CEL-2000, CEL-4000, CEL-5000).

Key Dates

Recommendation

While the clinical data for Multikine is highly compelling, showing significant survival benefits and a strong safety profile for a specific, underserved patient population, the company's severe financial constraints and 'going concern' doubt present substantial risks. The need to raise an additional $30 million for the confirmatory study, coupled with a history of losses and identified material weaknesses in internal controls, creates significant uncertainty. An investor should hold to monitor the progress of capital raising and the confirmatory study, as successful execution could lead to significant upside, but the current financial instability warrants caution against new investment.

Keywords

Biotechnology, Cancer Immunotherapy, Head and Neck Cancer, Multikine, Phase III Clinical Trial, FDA Approval, Oncology, LEAPS Technology, Rheumatoid Arthritis, SEC Filing, 10-K, Biologics, Clinical Development, Corporate Governance, Financial Reporting, Going Concern, Stock Split, PD-L1